Pleckstrin and Sec7 Domain Containing 3 (PSD3) (AA 327-339) antibody

Antigen: Pleckstrin and Sec7 Domain Containing 3 (PSD3)

Synonyms: EFA6R, HCA67, DKFZp761K1423, EFA6D, MGC6957, AI661273, BC003498, D430018P08, 4931420C21Rik, RGD1559968, PSD3

Epitope: AA 327-339

Clonality: Polyclonal

Host: Goat

Application: ELISA

Catalog no.: ABIN238650

Additional Information

Alternative name: PSD3 (aa 327-339)

Gene ID: 23362

Immunogen: C-QRTASPDSKESSK

Format: Affinity-purified

Description: All names and symbols: PSD3, pleckstrin and Sec7 domain containing 3, DKFZp761K1423, EFA6R, HCA67, ADP-ribosylation factor guanine nucleotide factor 6, hepatocellular carcinoma-associated antigen 67. Official Symbol: PSD3 . RefSeq number(s): NP_056125.3, NP_996792.1

Specificity: This antibody is expected to recognise the reported isoform (NP_056125.3). Human

Application Details

Application Notes: Peptide ELISA: antibody detection limit dilution 1:16,000. Western Blot: Preliminary experiments gave an approx 38-40kDa band in Human Brain (Cerebellum and Amygdala) lysates after 0.3µg/ml antibody staining. Please note that currently we cannot find an explanation in the literature for the band we observe given the calculated size of 116kDa according to NP_056125.3. The 38-40kDa band was successfully blocked by incubation with the immunizing peptide. We would appreciate any feedback from people in the field - have any results been reported with other antibodies/lysates? Have any further splice variants/modified forms been reported?

Purification: Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.

Buffer: Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

Storage: Aliquot and store at -20°C. Minimize freezing and thawing.

Restrictions: For Research Use only

Publications

Publications: Pils, Horak, Gleiss et al.: "Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival." in: Cancer, Vol. 104, Issue 11, pp. 2417-29, 2005 (PubMed).